CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

(2019) Paul Daniel et al.   Frontiers in Oncology

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?

(2019) Oren J. Becher   EBioMedicine

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

(2019) Jiayi Yu et al.   CLINICAL CANCER RESEARCH

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide

(2019) Rui-Chao Chai et al.   Frontiers in Genetics

Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma

(2019) Jia Wang et al.   CNS Neuroscience & Therapeutics

DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide

(2019) Mengting Zhao et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway

(2019) Xiao Yu et al.   LIFE SCIENCES

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib

(2019) Paiyun Li et al.   PLoS One

Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial

(2018) M Arnedos et al.   ANNALS OF ONCOLOGY

Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins

(2018) Jingshan Tong et al.   CANCER RESEARCH

Temozolomide-associated hypermutation in gliomas

(2018) Serah Choi et al.   NEURO-ONCOLOGY

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer

(2018) Kyle Knickelbein et al.   ONCOGENE

Current Challenges and Opportunities in Treating Glioblastoma

(2018) Andrea Shergalis et al.   PHARMACOLOGICAL REVIEWS

PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors

(2018) Dongshi Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma

(2018) Jennie W. Taylor et al.   JOURNAL OF NEURO-ONCOLOGY

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

(2018) Shabierjiang JIAPAER et al.   NEUROLOGIA MEDICO-CHIRURGICA

CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

(2018) Shom Goel et al.   TRENDS IN CELL BIOLOGY

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

(2018) Xiaoyue Chen et al.   Nature Communications

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

(2018) Kamal Pandey et al.   INTERNATIONAL JOURNAL OF CANCER

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

(2018) Priya K. Gopalan et al.   Oncotarget

FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors

(2017) Jingshan Tong et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions

(2017) Smruthi Vijayaraghavan et al.   Targeted Oncology

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer

(2017) Esther S. Kim et al.   Targeted Oncology

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer

(2017) Fengquan Chen et al.   Anti-Cancer Agents in Medicinal Chemistry

GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment

(2016) Jianlong Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

(2016) J Tong et al.   ONCOGENE

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors

(2016) Minghui Liu et al.   Oncotarget

Targeting Breast Cancer with CDK Inhibitors

(2015) Erica L. Mayer   Current Oncology Reports

PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma

(2013) Kelly L. Barton et al.   PLoS One

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

(2010) K. Michaud et al.   CANCER RESEARCH

Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues

(2010) Dante Amelio et al.   RADIOTHERAPY AND ONCOLOGY